Bristol-Myers Squibb ($BMY) is following up its lackluster third-quarter results with almost 480 layoffs. As Pharmalot reports,
the company notified the New Jersey government that it would scale back
in Plainsboro, which means the cuts will hit its sales operations.
The exact number of jobs to be cut, according to the state notification, is 479, Pharmalot reports. The Plainsboro facility mostly revolves around training and administrative support for the sales force.
Bristol-Myers is, of course, not alone in announcing layoffs and cutbacks recently. The most high-profile job-cutting plans are Sanofi's ($SNY) in France, where officials have not only publicly denounced the cuts but persuaded the company to rewind at least some of them. Other Big Pharmas with hundreds of cuts in the news recently include Abbott Laboratories ($ABT) (550 across several business units), Pfizer ($PFE) (300, mostly in sales) and Johnson & Johnson ($JNJ) (130 in Alzheimer's R&D).
The exact number of jobs to be cut, according to the state notification, is 479, Pharmalot reports. The Plainsboro facility mostly revolves around training and administrative support for the sales force.
Bristol-Myers is, of course, not alone in announcing layoffs and cutbacks recently. The most high-profile job-cutting plans are Sanofi's ($SNY) in France, where officials have not only publicly denounced the cuts but persuaded the company to rewind at least some of them. Other Big Pharmas with hundreds of cuts in the news recently include Abbott Laboratories ($ABT) (550 across several business units), Pfizer ($PFE) (300, mostly in sales) and Johnson & Johnson ($JNJ) (130 in Alzheimer's R&D).
No comments:
Post a Comment